ORBIMED ADVISORS LLC — 13F Holdings & Portfolio
CIK 1055951 · latest 13F-HR filed 2026-05-15
ORBIMED ADVISORS LLC manages $5.05B in 13F-reported U.S. long-equity assets across 114 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are EWTX (9.69%), ELVN (6.18%), MDXH (5.67%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 23 new positions, exited 21, added to 33, and trimmed 41.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$5.05B
Long-equity book
114
Distinct positions
2026-03-31
Filed 2026-05-15
+23 / −21 / ↑33 / ↓41
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ENLIVEN THERAPEUTICS INC$189.4M +154.5%
- EDGEWISE THERAPEUTICS INC$103.7M +26.9%
- CORVUS PHARMACEUTICALS INC$49.7M +90.0%
- XENON PHARMACEUTICALS INC$41.6M +207.5%
- PRAXIS PRECISION MEDICINES I$27.7M +99.5%
Top Trims
- ELI LILLY & CO-$105.9M -32.7%
- UPSTREAM BIO INC-$103.3M -66.9%
- BOSTON SCIENTIFIC CORP-$81.2M -35.2%
- ALNYLAM PHARMACEUTICALS INC-$75.5M -65.7%
- EDWARDS LIFESCIENCES CORP-$58.6M -37.3%
New Positions
- ASTRAZENECA PLC$132.2M
- MYRIAD GENETICS INC$122.9M
- MERCK & CO INC$79.8M
- AVITA MEDICAL INC$42.5M
- GUARDANT HEALTH INC$40.2M
Exited Positions
- TERNS PHARMACEUTICALS INC$87.0M
- APELLIS PHARMACEUTICALS INC$61.0M
- THE CIGNA GROUP$56.4M
- RAPT THERAPEUTICS INC$55.6M
- UNITED THERAPEUTICS CORP DEL$51.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $488.8M | 9.69% | 15,518,492 | SH |
| 2 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $312.0M | 6.18% | 7,959,538 | SH |
| 3 | MDXHEALTH SA Call | MDXH | B5950S113 | $285.9M | 5.67% | 124,306,000 | SH |
| 4 | ELI LILLY & CO | LLY | 532457108 | $217.8M | 4.32% | 236,800 | SH |
| 5 | SINOVAC BIOTECH LTD | SVA | P8696W104 | $184.5M | 3.66% | 2,718,735 | SH |
| 6 | AVITA MEDICAL INC Call | RCEL | 05380C102 | $154.4M | 3.06% | 40,966,100 | SH |
| 7 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $149.5M | 2.96% | 2,382,100 | SH |
| 8 | SIONNA THERAPEUTICS INC | SION | 829401108 | $141.5M | 2.81% | 3,530,702 | SH |
| 9 | ASTRAZENECA PLC | AZN | G0593M107 | $132.2M | 2.62% | 670,200 | SH |
| 10 | MYRIAD GENETICS INC | MYGN | 62855J104 | $122.9M | 2.44% | 125,000,000 | PRN |
| 11 | MBX BIOSCIENCES INC | MBX | 55287L101 | $108.6M | 2.15% | 3,637,887 | SH |
| 12 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $104.8M | 2.08% | 7,165,006 | SH |
| 13 | ARGENX SE | ARGX | 04016X101 | $100.0M | 1.98% | 136,900 | SH |
| 14 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $98.5M | 1.95% | 1,230,600 | SH |
| 15 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $96.2M | 1.91% | 208,700 | SH |
| 16 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $80.5M | 1.60% | 15,219,994 | SH |
| 17 | MERCK & CO INC | MRK | 58933Y105 | $79.8M | 1.58% | 663,400 | SH |
| 18 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $71.1M | 1.41% | 1,475,403 | SH |
| 19 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $69.8M | 1.38% | 3,027,328 | SH |
| 20 | DISC MEDICINE INC | IRON | 254604101 | $68.3M | 1.35% | 1,067,550 | SH |
| 21 | ARS PHARMACEUTICALS INC | SPRY | 82835W108 | $66.6M | 1.32% | 8,288,510 | SH |
| 22 | CG ONCOLOGY INC | CGON | 156944100 | $64.2M | 1.27% | 948,267 | SH |
| 23 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $61.6M | 1.22% | 1,059,971 | SH |
| 24 | STRYKER CORPORATION | SYK | 863667101 | $60.0M | 1.19% | 182,500 | SH |
| 25 | BRISTOL-MYERS SQUIBB CO | BMY | 110122108 | $56.1M | 1.11% | 925,000 | SH |
| 26 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $55.6M | 1.10% | 2,052,900 | SH |
| 27 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $55.6M | 1.10% | 172,500 | SH |
| 28 | PFIZER INC | PFE | 717081103 | $54.7M | 1.08% | 1,946,500 | SH |
| 29 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $52.9M | 1.05% | 2,917,884 | SH |
| 30 | NATERA INC | NTRA | 632307104 | $52.4M | 1.04% | 262,000 | SH |
| 31 | ABIVAX SA | ABVX | 00370M103 | $51.9M | 1.03% | 465,700 | SH |
| 32 | UPSTREAM BIO INC | UPB | 91678A107 | $51.2M | 1.02% | 5,693,589 | SH |
| 33 | DANAHER CORP DEL | DHR | 235851102 | $50.4M | 1.00% | 265,800 | SH |
| 34 | CARIS LIFE SCIENCES INC | CAI | 142152107 | $50.2M | 0.99% | 2,806,811 | SH |
| 35 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $41.6M | 0.82% | 181,977 | SH |
| 36 | SHATTUCK LABS INC | STTK | 82024L103 | $40.5M | 0.80% | 6,306,127 | SH |
| 37 | AVITA MEDICAL INC | RCEL | 05380C102 | $40.5M | 0.80% | 40,500,000 | PRN |
| 38 | GUARDANT HEALTH INC | GH | 40131M109 | $40.2M | 0.80% | 435,200 | SH |
| 39 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $39.4M | 0.78% | 119,000 | SH |
| 40 | PRELUDE THERAPEUTICS INC | PRLD | 74065P101 | $37.3M | 0.74% | 10,909,256 | SH |
| 41 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $36.3M | 0.72% | 999,000 | SH |
| 42 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $36.2M | 0.72% | 213,921 | SH |
| 43 | UNIQURE NV | QURE | N90064101 | $34.9M | 0.69% | 2,136,149 | SH |
| 44 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $34.1M | 0.68% | 2,693,929 | SH |
| 45 | ELEVANCE HEALTH INC FORMERLY | ELV | 036752103 | $33.6M | 0.67% | 114,700 | SH |
| 46 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $32.8M | 0.65% | 4,715,864 | SH |
| 47 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $31.0M | 0.61% | 1,196,955 | SH |
| 48 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $29.3M | 0.58% | 2,454,400 | SH |
| 49 | ESPERION THERAPEUTICS INC NE | ESPR | 29664W105 | $29.0M | 0.57% | 10,570,300 | SH |
| 50 | NEUROPACE INC | NPCE | 641288105 | $27.6M | 0.55% | 2,096,527 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $5.05B | 114 | 0001172661-26-002369 |
| 2025-12-31 | 2026-02-17 | $4.90B | 108 | 0001172661-26-001119 |
| 2025-09-30 | 2025-11-14 | $4.26B | 110 | 0001172661-25-005047 |